Business
Time to debunk anti-vaxxer myths: CSL CEO – The Australian Financial Review
Demand for CSL’s core plasma products and surging government orders for flu vaccines has resulted in the biotech giant lifting the bottom end of its 2021 profit…
“We don’t have the ability to just turn on a dime and start making more flu vaccines … when we start the manufacturing process it’s pretty well done… and to turn and make more is very difficult late in the season, but we’ve had good yield
-
Noosa News24 hours agoPolice make emergency declaration after fire at storage facility north of Brisbane
-
Noosa News13 hours agoBrisbane news LIVE updates: Burpengary storage facility engulfed in fire | Toll road laws passed in Parliament
-
General20 hours agoWhite phosphorus, blood-red money. Australian Super profiting from genocide
-
General19 hours agoIsraeli fire kills 41 in Gaza, health officials say, as rival militia emerges to challenge Hamas